KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Depreciation and Depletion (2020 - 2024)

Historic Depreciation and Depletion for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Q4 2024 value amounting to $6.2 million.

  • Recursion Pharmaceuticals' Depreciation and Depletion rose 4761.9% to $6.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $18.3 million, marking a year-over-year increase of 1437.5%. This contributed to the annual value of $18.3 million for FY2024, which is 1509.43% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Depreciation and Depletion stood at $6.2 million for Q4 2024, which was up 4761.9% from $4.0 million recorded in Q3 2024.
  • In the past 5 years, Recursion Pharmaceuticals' Depreciation and Depletion registered a high of $6.2 million during Q4 2024, and its lowest value of $1.0 million during Q1 2020.
  • Over the past 5 years, Recursion Pharmaceuticals' median Depreciation and Depletion value was $2.8 million (recorded in 2022), while the average stood at $2.9 million.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first soared by 14000.0% in 2021, then crashed by 476.19% in 2024.
  • Recursion Pharmaceuticals' Depreciation and Depletion (Quarter) stood at $1.1 million in 2020, then skyrocketed by 127.27% to $2.5 million in 2021, then rose by 24.0% to $3.1 million in 2022, then surged by 35.48% to $4.2 million in 2023, then soared by 47.62% to $6.2 million in 2024.
  • Its last three reported values are $6.2 million in Q4 2024, $4.0 million for Q3 2024, and $4.1 million during Q2 2024.